Nuvation Bio Files Definitive Additional Materials
Ticker: NUVB · Form: DEFA14A · Filed: Apr 21, 2026 · CIK: 0001811063
Sentiment: neutral
Topics: proxy-filing, sec-filing, materials
TL;DR
Nuvation Bio dropped more proxy docs 4/21. Check for shareholder votes.
AI Summary
Nuvation Bio Inc. filed a Definitive Additional Materials (DEFA14A) on April 21, 2026. The filing, with SEC Accession Number 0001140361-26-015827, contains 30966 documents. The company's mailing and business address is 1500 Broadway, Suite 1401, New York, NY 10036.
Why It Matters
This filing indicates that Nuvation Bio is providing supplementary materials related to proxy solicitations, which could contain important updates for shareholders regarding company decisions or proposals.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of additional proxy materials and does not inherently present new financial risks.
Key Numbers
- 30966 — Documents (Size of the complete submission text file)
Key Players & Entities
- Nuvation Bio Inc. (company) — Filer
- 0001140361-26-015827 (dollar_amount) — SEC Accession Number
- 2026-04-21 (dollar_amount) — Filing Date
- 1500 BROADWAY SUITE 1401 NEW YORK NY 10036 (dollar_amount) — Mailing and Business Address
FAQ
What type of filing is this DEFA14A?
This filing is for Additional definitive proxy soliciting materials and Rule 14(a)(12) material.
What is the SEC Accession Number for this filing?
The SEC Accession Number is 0001140361-26-015827.
When was this filing accepted by the SEC?
The filing was accepted on 2026-04-21.
What is Nuvation Bio Inc.'s business address?
Nuvation Bio Inc.'s business address is 1500 BROADWAY SUITE 1401 NEW YORK NY 10036.
What is the SIC code for Nuvation Bio Inc.?
The SIC code for Nuvation Bio Inc. is 2834, which falls under Pharmaceutical Preparations (CF Office: 03 Life Sciences).
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 21, 2026 regarding Nuvation Bio Inc. (NUVB).